Currently Enrolling Studies:
MARIN: A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- The main objective of this study is to evaluate the durability of effect of the study drug in subjects with symptomatic orthostatic hypotension (nOH), due to Multiple System Atrophy (MSA), Parkinson's Disease (PD), or Pure Autonomic Failure (PAF) compared with placebo (PBO) over the course of 22 weeks.
WMMS: Development of a Wearable Multi-Modal Monitoring System (WMMS) to determine causes of Falls in Parkinson's Disease and Atypical Parkinsonian Disorders
- The aim of this study is to develop and test clinical applications of a wearable device that will continuously record multiple physiologic parameters such as blood pressure, heart rate, motion, brain activity etc. in patient's real life settings.
- This study is recruiting participants with Parkinson's disease and Atypical Parkinsonian Disorders such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD) and Multiple System Atrophy (MSA).
MSA-101: Randomized, Double-Blind, Placebo-Controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
- This study is testing a treatment called glial cell line-derived neurotrophic factor (GDNF) gene transfer to evaluate if it helps people with Multiple System Atrophy (MSA). During the procedure GDNF is delivered to a part of the brain called the putamen.
- The study will evaluate the safety and tolerability of the treatment and possible improvement in the clinical features of MSA.
- Expected to start enrolling: late Spring 2021
- You can find more information on: https://www.clinicaltrials.gov/ct2/show/NCT04680065
Enrollment Closed studies:
M-STAR: A randomized, Double-Blind, Placebo Controlled to Evaluate Efficacy and Safety of BHV3241 in Patients with MSA
- The main objective of this study is to evaluate whether the study drug can slow down disease progression in individuals with multiple system atrophy.
- People with multiple system atrophy will use an oral medication (study drug or placebo) twice daily for about 11 months. The study will involve up to seven visits. Neurological examination and neuropsychological testing will be performed at each visit. A study partner/caregiver is required.
For further information about this and other studies, please contact Aishwarya Niraula by email email@example.com or phone 858-246-3190.